Orgenesis (ORGS) investor relations material

Executive summary

• Revenue increased 95% year-over-year to $1.0 million, driven by cell process development and hospital services.

• Net loss for 2024 was $49.0 million, an improvement from $64.9 million in 2023.

• Gross loss narrowed to $0.9 million from $5.7 million in the prior year.

• Significant impairment charges of $18.3 million were recorded, including full impairment of goodwill and intangible assets.

• The company faces substantial doubt about its ability to continue as a going concern due to negative cash flows and limited liquidity.

Financial highlights

• Revenues: $1.0 million in 2024, up from $0.5 million in 2023.

• Cost of revenues: $1.9 million, down 69% year-over-year.

• Operating loss: $39.8 million, improved from $53.6 million in 2023.

• Net loss: $49.0 million, compared to $64.9 million in 2023.

• Cash and cash equivalents at year-end: $0.1 million.

• Working capital deficit: $26.2 million at December 31, 2024.

• Outstanding debt: $65.8 million as of December 31, 2024.

Outlook and guidance

• Management expects current and projected cash resources will not be sufficient to meet obligations for the next 12 months.

• Plans include raising additional capital, seeking payment delays, and reducing expenses.

• Substantial doubt remains about the ability to continue as a going concern without new funding.